List of Excipients in Branded Drug QUETIAPINE FUMARATE

« Back to Dashboard

Generic Drugs Containing QUETIAPINE FUMARATE

Company	Ingredient	NDC	Excipient
Hikma Pharmaceuticals USA Inc	quetiapine fumarate	0054-0220	CELLULOSE, MICROCRYSTALLINE
Hikma Pharmaceuticals USA Inc	quetiapine fumarate	0054-0220	LACTOSE
Hikma Pharmaceuticals USA Inc	quetiapine fumarate	0054-0220	MAGNESIUM STEARATE
Hikma Pharmaceuticals USA Inc	quetiapine fumarate	0054-0220	POVIDONE K30

What are the Most Frequently-Used Excipients in QUETIAPINE FUMARATE?

# Of NDCs	Excipient
2	ALUMINUM OXIDE
11	ANHYDROUS CITRIC ACID
1	ANHYDROUS DIBASIC CALCIUM PHOSPHATE
1	ANHYDROUS LACTOSE

Quetiapine Fumarate Excipient Strategy and Commercial Opportunities

Last updated: September 24, 2026

Quetiapine fumarate is a mature antipsychotic active pharmaceutical ingredient with broad generic competition in immediate-release and extended-release tablets. The strongest commercial opportunities are in modified-release performance, patient-friendly dosage forms, excipient optimization, supply reliability, and differentiated regulatory submissions rather than in basic tablet replication.

Quetiapine products must balance dose flexibility, dissolution control, tablet size, swallowability, mechanical strength, impurity control, and low-cost manufacturing. The active ingredient is used primarily in schizophrenia, bipolar disorder, and adjunctive treatment of major depressive disorder. FDA-approved products include immediate-release quetiapine tablets and quetiapine extended-release tablets marketed originally as Seroquel and Seroquel XR. [1-3]

What excipients are used in quetiapine fumarate tablets?

Quetiapine fumarate tablets commonly use lactose, microcrystalline cellulose, dibasic calcium phosphate, povidone, sodium starch glycolate, magnesium stearate, hypromellose, polyethylene glycol, talc, titanium dioxide, and colorants. The exact composition depends on the dosage form, strength, manufacturer, and release profile.

Immediate-release quetiapine excipient architecture

Immediate-release tablets generally require rapid disintegration and reproducible dissolution across multiple strengths. A representative formulation strategy includes:

Formulation function	Common excipient choices	Commercial purpose
Dilution and compression	Lactose monohydrate, microcrystalline cellulose, dibasic calcium phosphate	Controls tablet mass, density, and hardness
Granulation and binding	Povidone	Improves granule strength and content uniformity
Disintegration	Sodium starch glycolate, crospovidone, croscarmellose sodium	Promotes rapid tablet breakup
Lubrication	Magnesium stearate	Reduces ejection force and tooling adhesion
Film coating	Hypromellose, polyethylene glycol, talc, titanium dioxide	Protects the tablet and supports identification
Color differentiation	Iron oxides and other approved colorants	Reduces medication-error risk between strengths

Immediate-release quetiapine tablets are generally produced by wet granulation or direct compression, depending on powder flow, dose loading, and the selected excipient system. Wet granulation can improve content uniformity and compressibility but adds water exposure, drying cost, and process complexity. Direct compression reduces processing steps but requires stronger control of particle-size distribution, segregation, flow, and lubricant sensitivity.

The main development risk is not disintegration alone. Excessive lubricant concentration or over-lubrication can reduce tablet tensile strength and slow dissolution. High levels of hydrophilic binder can also alter wetting and drug release.

Extended-release quetiapine excipient architecture

Extended-release tablets require a matrix or membrane system that limits drug release over the intended dosing interval. Seroquel XR labeling identifies hypromellose as a key release-controlling excipient, with lactose, microcrystalline cellulose, sodium citrate, magnesium stearate, talc, titanium dioxide, and colorants also used in the tablet system. [2]

A typical hydrophilic matrix approach uses:

• Hypromellose to form a gel barrier after hydration.
• Microcrystalline cellulose and lactose to adjust tablet structure and erosion.
• Sodium citrate or another microenvironment modifier to control drug release and matrix hydration.
• Magnesium stearate at a controlled level to support manufacturing.
• A protective film coat for handling, appearance, and product identification.

The principal technical challenge is maintaining comparable dissolution across dose strengths. A formulation that performs acceptably at 50 mg may not scale proportionally to 300 or 400 mg because tablet geometry, drug loading, matrix thickness, and diffusion paths change with strength.

Which excipient strategies are most attractive for quetiapine products?

The most commercially relevant strategies are low-risk substitutions that improve manufacturability, patient use, or supply continuity without materially changing the clinical profile.

1. Lactose-free and low-lactose formulations

Lactose is used widely as a filler in quetiapine products. A lactose-free formulation can target patients with lactose intolerance, manufacturers seeking simplified excipient declarations, or markets where lactose supply is constrained.

Potential replacement systems include:

• Microcrystalline cellulose and mannitol for direct compression.
• Dibasic calcium phosphate for density and tablet strength.
• Spray-dried mannitol for improved flow and mouthfeel.
• Pregelatinized starch where binding and disintegration must be combined.

The tradeoff is that replacing lactose can change bulk density, tablet size, friability, dissolution, and coating behavior. A lactose-free claim may have commercial value, but it must be supported by a complete comparative quality package.

2. Reduced-tablet-size products

Quetiapine doses can be high, particularly in schizophrenia and bipolar disorder maintenance therapy. Large tablets may reduce adherence for patients with dysphagia or psychiatric illness.

High-density fillers, roller compaction, optimized granule porosity, and higher drug-loading processes can reduce tablet volume. The opportunity is strongest for higher-dose immediate-release and extended-release strengths, where swallowability is a practical limitation.

A smaller tablet must still meet:

• Content uniformity.
• Breaking or scoring requirements where applicable.
• Mechanical robustness.
• Dissolution specifications.
• Coating uniformity.
• Stability through distribution.

3. Orally disintegrating and orally dispersible dosage forms

An orally disintegrating tablet, oral granule, or dispersible tablet could address patients who have difficulty swallowing conventional tablets. Quetiapine’s dose range makes taste masking and unit-dose handling central formulation issues.

Relevant excipient tools include:

• Mannitol for cooling mouthfeel and bulk.
• Crospovidone or low-substituted hydroxypropyl cellulose for rapid disintegration.
• Coated or complexed quetiapine particles for taste masking.
• Flavors and sweeteners compatible with psychiatric populations.
• Sublimation or porous-tablet technologies for fast water penetration.

The commercial case depends on whether the product delivers a meaningful administration advantage without requiring a costly new clinical program. A conventional ANDA may be unavailable for a genuinely new dosage form, making a 505(b)(2) pathway more likely. FDA’s regulatory treatment depends on the formulation, labeling, dosage form, and reliance on the reference product. [4]

4. Sprinkle and multiparticulate formulations

A sprinkle formulation could target patients unable to swallow tablets but able to consume drug mixed with soft food. Multiparticulate systems can separate drug release from tablet geometry and may support dose flexibility.

The formulation must address:

• Uniform drug distribution in the food vehicle.
• Stability after opening.
• Dose recovery from the container.
• Taste and mouthfeel.
• Food-effect behavior.
• Abuse-deterrence and accidental exposure considerations.
• Maintenance of the intended release profile for extended-release products.

A sprinkle product with modified-release particles may have greater differentiation than a conventional immediate-release tablet, but it also creates more demanding in vitro, in vivo, and labeling requirements.

What patent protection covers quetiapine fumarate products?

The original quetiapine compound and core product patents are expired or historically expired in the United States. Quetiapine fumarate therefore has a mature generic market, and basic composition-of-matter protection does not represent the principal entry barrier.

Patent or product area	Relevance
Quetiapine compound and fumarate salt	Historical originator protection; no longer the primary U.S. barrier
Immediate-release tablet	Generic competition is established
Extended-release tablet	Historical formulation and product-specific patent issues affected early entry
New delivery systems	Potentially protectable if supported by novelty and non-obviousness
New dosage strengths or combinations	Potentially protectable, but claim scope and obviousness risk are significant
Manufacturing process	May create targeted protection if the process improves impurity, yield, particle size, or release control

The main current IP opportunity lies in formulation and process claims. Examples include controlled-release matrices, multiparticulate systems, taste-masked particles, low-dose variability systems, abuse-resistant platforms, and manufacturing processes that control quetiapine-related impurities.

Patent strength depends on whether the claim covers a real technical limitation rather than a routine excipient substitution. A claim reciting a conventional filler replacement is vulnerable if the substitution would have been predictable to a formulation scientist. Stronger claims may tie a specific excipient ratio or process parameter to an unexpected dissolution, stability, bioavailability, or manufacturing result.

What is the FDA regulatory status of quetiapine fumarate?

Quetiapine fumarate is FDA-approved in immediate-release tablets and extended-release tablets. The reference products are Seroquel and Seroquel XR, originally associated with AstraZeneca. Generic quetiapine products have been approved through the ANDA pathway, while differentiated dosage forms may require a 505(b)(2) application. [1-4]

Orange Book and Paragraph IV considerations

The FDA Orange Book identifies approved drug products, reference-listed drugs, patent information, and exclusivity data. [5] For a mature product such as quetiapine fumarate, an ANDA applicant must evaluate:

1. Current Orange Book patent listings.
2. Product-specific exclusivity.
3. Certification requirements under Hatch-Waxman.
4. Whether listed patents remain enforceable.
5. Whether the proposed product has the same dosage form, strength, route, and release characteristics.
6. Any Paragraph IV litigation or settlement restrictions affecting launch timing.

A Paragraph IV challenge may still be commercially relevant for a newly listed formulation patent, but the core quetiapine market no longer depends on a single active originator patent. Applicants should separate historical litigation from currently enforceable rights.

When did quetiapine lose exclusivity?

Quetiapine’s U.S. market exclusivity ended in stages rather than on one universal date. Seroquel received FDA approval in 1997, and Seroquel XR received approval in 2007. Generic immediate-release and extended-release products entered after the relevant patent and regulatory protections expired or were resolved. [1-3]

The practical result is:

• Immediate-release quetiapine is a mature, price-competitive generic market.
• Extended-release quetiapine retains more formulation and manufacturing complexity.
• New dosage forms may obtain separate regulatory exclusivity if they qualify under FDA rules.
• Patent protection for a new delivery system would depend on the claims and filing date, not on the expired originator patents.

What commercial opportunities exist for quetiapine fumarate?

The commercial opportunity is strongest where a product solves a specific manufacturing or patient-use problem.

High-value opportunity areas

Opportunity	Commercial rationale	Main risk
Low-cost immediate-release tablets	Large generic demand and simple supply chain	Severe price competition
Extended-release tablets	Higher technical barrier and fewer qualified suppliers	Dissolution and bioequivalence complexity
Smaller high-dose tablets	Improved swallowability	Compression and stability tradeoffs
Lactose-free tablets	Differentiated excipient profile	Limited willingness to pay
Orally disintegrating tablets	Patient convenience	Taste masking and 505(b)(2) complexity
Sprinkle formulations	Supports dysphagia populations	Food-effect and dose-uniformity studies
Dual-source excipient platform	Reduces supply disruption	Requires comparability and validation
Regional manufacture	Reduces freight and regulatory dependency	Scale and quality-system investment

The generic immediate-release market is difficult to differentiate on price alone. Suppliers with reliable manufacturing, low defect rates, and broad strength coverage may still gain share because hospitals, wholesalers, and pharmacy buyers value continuity of supply.

Extended-release products may offer better margins because process development and bioequivalence requirements are more demanding. The strongest strategy is usually a platform that supports multiple strengths with a common matrix architecture and tightly controlled scale-up parameters.

How strong is the quetiapine fumarate patent estate?

The legacy patent estate is weak as a barrier to standard generic entry but potentially useful for new product development.

Patent strength by asset type

Asset type	Relative strength	Reason
Basic quetiapine composition claims	Low for new entry	Historical protection has expired
Standard immediate-release tablet	Low	Established generic technology
Conventional film coating	Low	Routine pharmaceutical practice
Specific extended-release matrix	Moderate	May require defined composition and performance
Novel multiparticulate release system	Moderate to high	More difficult to design around if clinically useful
Taste-masked ODT or sprinkle product	Moderate	Depends on technology and sensory data
Impurity-control manufacturing process	Moderate	Stronger if linked to measurable product-quality improvement
Supply-chain or excipient substitution claims	Low to moderate	Vulnerable if technically routine

Patent filings should focus on measurable formulation performance, not broad claims to quetiapine combined with ordinary excipients. A defensible estate may include composition claims, process claims, dissolution-profile claims where permitted, and backup claims covering particle engineering, coating thickness, matrix ratios, and manufacturing conditions.

What manufacturing and IP barriers affect generic launch?

The main barriers are technical and regulatory:

• Achieving bioequivalence for extended-release products.
• Controlling dose dumping under alcohol exposure where required.
• Matching dissolution across multiple media and strengths.
• Managing powder segregation during high-dose manufacturing.
• Controlling degradation products and residual solvents.
• Demonstrating stability in the selected packaging system.
• Securing qualified sources for hypromellose, lactose, microcrystalline cellulose, and specialty disintegrants.
• Establishing a scalable coating process.
• Avoiding infringement of any later-filed formulation or process patents.

Packaging can also affect commercial performance. High-dose quetiapine products may require moisture-barrier blistering or bottles with desiccants, depending on stability data. Unit-dose packaging can support hospital sales but increases material and line costs.

How does quetiapine compare with competing antipsychotic products?

Quetiapine competes with generic aripiprazole, risperidone, olanzapine, ziprasidone, lurasidone, and other atypical antipsychotics. Its formulation opportunity differs by product:

Drug	Main formulation opportunity	Competitive consideration
Quetiapine	Extended release, ODT, sprinkle, smaller high-dose tablets	High dose burden and mature generic pricing
Aripiprazole	ODT and long-acting injectable products	Stronger injectable differentiation
Risperidone	ODT, oral solution, long-acting injectables	Broad dosage-form competition
Olanzapine	ODT and long-acting injectable	Established patient-friendly options
Lurasidone	Tablet optimization and supply economics	More recent product lifecycle
Ziprasidone	Capsule and food-related administration considerations	Smaller commercial base in some markets

Quetiapine’s opportunity is tied to its broad dose range and use across several psychiatric indications. Its disadvantages are generic price pressure, sedation-related tolerability concerns, and the technical burden of high-dose products.

Key Takeaways

• Quetiapine fumarate is a mature generic market with limited value in standard immediate-release replication.
• The most commercially attractive excipient strategies involve extended-release control, smaller tablets, lactose-free systems, ODTs, sprinkle products, and supply-chain resilience.
• Hypromellose remains central to many extended-release matrix strategies.
• Conventional excipient substitutions are weak patent candidates unless linked to unexpected performance or manufacturing benefits.
• New dosage forms may require a 505(b)(2) pathway rather than a conventional ANDA.
• Orange Book review remains necessary for any proposed generic or differentiated product because later-listed formulation and process patents can affect launch timing.
• Extended-release products offer higher technical barriers and potentially better margins than immediate-release tablets.
• A commercially useful patent estate should cover formulation composition, process conditions, particle engineering, and performance-linked technical results.

FAQs About Quetiapine Fumarate Excipient and Commercial Strategy

What is the best disintegrant for quetiapine immediate-release tablets?

Sodium starch glycolate, crospovidone, and croscarmellose sodium are credible candidates. The optimal choice depends on tablet hardness, granulation method, lubricant level, dissolution target, and moisture sensitivity.

Can quetiapine fumarate be formulated without lactose?

Yes. Microcrystalline cellulose, mannitol, dibasic calcium phosphate, and starch-based systems can replace lactose, subject to comparative dissolution, stability, and bioequivalence requirements.

Is an extended-release quetiapine product harder to develop than an immediate-release tablet?

Yes. Extended-release products require control of matrix hydration, dissolution across strengths, food effects, and bioequivalence. The development burden is materially higher.

Can an orally disintegrating quetiapine product use the ANDA pathway?

Only if it meets the applicable sameness and regulatory requirements for an approved reference product. A materially different dosage form or reliance strategy may require a 505(b)(2) application.

Are quetiapine excipient combinations patentable?

They can be patentable when the claimed combination is novel, non-obvious, adequately described, and tied to a demonstrated technical result. Routine substitution of one filler or disintegrant for another is more vulnerable to invalidity challenges.

References

1. U.S. Food and Drug Administration. (1997). Seroquel (quetiapine fumarate) tablets: Prescribing information.
2. U.S. Food and Drug Administration. (2007). Seroquel XR (quetiapine fumarate) extended-release tablets: Prescribing information.
3. DailyMed. (n.d.). Quetiapine fumarate tablets and extended-release tablets: Product labeling. U.S. National Library of Medicine.
4. U.S. Food and Drug Administration. (2024). Applications covered by 505(b)(2).
5. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.